ClinicalTrials.gg
CompletedNCT01760447Updated Sep 23, 2022Results posted

A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)

A Phase 3 interventional study of Sitagliptin plus metformin and Placebo to metformin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-09-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Dec 2011, registered Jan 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
66th of 197
223 · median 102
Started
2011
with 12 others
Phase 3
74 of 198
none open now
Registered
128th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 66th largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2011, is one of 74 in phase 3, and was the 128th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of the addition of sitagliptin (administered as MK-0431A or MK-0431A XR) relative to the addition of placebo on glycated hemoglobin (A1C), and the safety and tolerability of the addition of sitagliptin, in pediatric participants (ages 10-17 years) with type 2 diabetes mellitus with inadequate glycemic control on metformin therapy (alone or in combination with insulin). The primary hypothesis is that the addition of sitagliptin reduces glycated hemoglobin (A1C) more than the addition of placebo after 20 weeks of treatment.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For MK-0431A-170 base study and MK-0431A-289:

    • Has type 2 diabetes mellitus (T2DM)
    • Is on metformin monotherapy (≥1500 mg/day) for ≥12 weeks with (A1C) ≥6.5% and ≤10.0% OR is on stable doses of metformin (≥1500 mg/day) and insulin for ≥12 weeks with an A1C ≥7.0% and ≤10%. NOTE: Participants on a daily dose of metformin greater than or equal to 1000 mg/day, but less than 1500 mg/day may be eligible if there is documentation that higher doses are not tolerated.
    • Participant and a family member or adult closely involved in the daily activities will participate in the participant's treatment and study protocol (i.e., available for telephone calls, study visits and administration of study medication as needed).
    • Male, or female who is unlikely to conceive (non-sterilized, and is not sexually active or agrees to abstain from heterosexual activity or agrees to use an adequate method of ) during the study and for 14 days after the last dose of study drug
  • For MK-0431A-170 extension protocol:

    • Has completed the P170 base study
    • Participant and a family member or adult closely involved in the daily activities will participate in the participant's treatment and study protocol (i.e., available for telephone calls, study visits and administration of study medication as needed).
    • Male, or female who is unlikely to conceive (non-sterilized, and is not sexually active or agrees to abstain from heterosexual activity or agrees to use an adequate method of contraception) during the study and for 14 days after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • For MK-0431A-170 base study and MK-0431A-289:

    • Has type 1 diabetes mellitus
    • Has monogenic diabetes or secondary diabetes
    • Has symptomatic hyperglycemia and/or moderate to large ketonuria and/or positive test for ketonemia, requiring immediate initiation of another antihyperglycemic agent
    • Has previously taken a dipeptidyl peptidase IV (DPP-4) inhibitor (such as sitagliptin, vildagliptin, alogliptin, saxagliptin, or linagliptin) or glucagon-like peptide-1 (GLP-1) receptor agonist (such as exenatide or liraglutide)
    • Is on or likely to require treatment for ≥2 consecutive weeks or repeated courses of (inhaled, nasal and topical corticosteroids are permitted)
    • Has undergone a surgical procedure within 4 weeks of study participation or has planned major surgery during the study
    • History of congenital heart disease or cardiovascular disease other than hypertension
    • History of active liver disease (other than non-alcoholic steatosis), including chronic active or C, primary biliary cirrhosis, or symptomatic gallbladder disease
    • Active neuropathy (such as nephrotic syndrome or glomerulonephritis)
    • Chronic myopathy, mitochondrial disorder or a progressive neurological or neuromuscular disorder
    • (HIV)
    • Hematological disorder (such as aplastic anemia, thrombocytopenia, myeloproliferative or myelodysplastic syndromes)
    • Is currently being treated for hyperthyroidism or is on thyroid hormone therapy and has not been on a stable dose for at least 6 weeks
    • History of for ≤5 years prior to study participation, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
    • History of idiopathic acute pancreatitis or chronic pancreatitis
    • History of recreational or illicit drug use, or of alcohol abuse or dependence (within the past year)
    • Has donated blood products or has had phlebotomy of >10% of estimated total blood volume within 8 weeks of study participation, or intends to donate blood products or receive blood products within the projected duration of the study
    • Is pregnant or breast-feeding, or is expecting to conceive or donate eggs during the study, including 14 days following the last dose of study drug
  • For MK-0431A-170 extension protocol:

    • Participant meets a study medication discontinuation criterion at the last visit of the MK-0431A-170 base study (Week 20)
    • Has taken the last dose of study medication for the MK-0431A-170 base study more than 14 days prior to Extension Visit 1
    • Has initiated another oral antihyperglycemic agent
    • Participant does not agree to refrain from participating in any other double-blind interventional study while participating in the P170 extension study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    Sitagliptin/Metformin

    Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.

    Drug: Sitagliptin plus metformin · Drug: Placebo to metformin · Drug: Insulin

  • Placebo comparator
    Metformin

    Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.

    Drug: Metformin · Drug: Placebo to sitagliptin plus metformin · Drug: Insulin

  • Experimental
    Sitagliptin/Metformin XR

    Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.

    Drug: Sitagliptin plus metformin XR · Drug: Placebo to metformin XR · Drug: Insulin

  • Placebo comparator
    Metformin XR

    Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.

    Drug: Insulin · Drug: Placebo to sitagliptin plus metformin XR · Drug: Metformin XR

Interventions

  • DrugSitagliptin plus metformin

    Drug pages: Sitagliptin · Metformin

    Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1700 mg or 2000 mg of metformin. Dosage of metformin was based on each participant's daily metformin dose prior to enrollment.

    Also known as: MK-0431A

  • DrugPlacebo to metformin

    Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to metformin.

  • DrugMetformin

    Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 1000 mg, 1700 mg or 2000 mg of metformin. Dosage was based on each participant's daily metformin dose prior to enrollment.

  • DrugPlacebo to sitagliptin plus metformin

    Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to sitagliptin plus metformin.

    Also known as: Placebo to MK-0431A

  • DrugSitagliptin plus metformin XR

    Drug pages: Sitagliptin · Metformin

    Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1500 mg or 2000 mg of metformin. Dosage of metformin XR was based on each participant's daily metformin dose prior to enrollment.

    Also known as: MK-0431A XR

  • DrugPlacebo to metformin XR

    Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to metformin XR.

  • Participants who met protocol-specific glycemic rescue criteria received insulin as glycemic rescue therapy; participants on background insulin had their insulin dose increased for glycemic rescue. During Weeks 20-54, for participants who were not on background insulin or rescued with insulin during Weeks 0-20 in the "Sitagliptin/Metformin" and "Metformin" arms (protocol MK-0431A-170), and during Weeks 0-54 for participants not on background insulin in the "Sitagliptin/Metformin XR" and "Metformin XR" arms (protocol MK-0431A-289), the type of insulin for glycemic rescue was specified to be insulin glargine.

  • DrugPlacebo to sitagliptin plus metformin XR

    Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to sitagliptin plus metformin XR.

    Also known as: Placebo to MK-0431A XR

  • DrugMetformin XR

    Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 1000 mg, 1500 mg or 2000 mg of metformin XR. Dosage was based on each participant's daily metformin dose prior to enrollment.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in A1C at Week 20

    Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline at Week 20 was estimated from a longitudinal data analysis model.

    Time frame: Baseline and Week 20

  2. Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-20

    The number of participants experiencing ≥1 adverse event during Weeks 0-20 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to Week 20

  3. Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-20

    The number of participants who discontinued from study drug due to an adverse event during Weeks 0-20 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to Week 20

  4. Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56

    The number of participants experiencing ≥1 adverse event during Weeks 0-56 were reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to approximately Week 56

  5. Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54

    The number of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to Week 54

Secondary outcomes

  1. Change From Baseline in A1C at Week 54

    A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline at Week 54 was estimated from a longitudinal data analysis model.

    Time frame: Baseline and Week 54

  2. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20

    Blood glucose was measured on a fasting basis. Mean change from baseline at Week 20 was estimated from a longitudinal data analysis model.

    Time frame: Baseline and Week 20

  3. Change From Baseline in FPG at Week 54

    Blood glucose was measured on a fasting basis. Mean change from baseline at Week 54 was estimated from a longitudinal data analysis model.

    Time frame: Baseline and Week 54

  4. Percentage of Participants With A1C at Goal (<7.0%) at Week 20

    Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<7.0%) at Week 20 was presented.

    Time frame: Week 20

  5. Percentage of Participants With A1C at Goal (<6.5%) at Week 20

    Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<6.5%) at Week 20 was presented.

    Time frame: Week 20

  6. Percentage of Participants With A1C at Goal (<7.0%) at Week 54

    Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<7.0%) at Week 54 was presented.

    Time frame: Week 54

  7. Percentage of Participants With A1C at Goal (<6.5%) at Week 54

    Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<6.5%) at Week 54 was presented.

    Time frame: Week 54

  8. Percentage of Participants Initiating Glycemic Rescue Therapy by Week 20

    Percentage of participants who initiated glycemic rescue therapy prior to Week 20 was reported.

    Time frame: Up to Week 20

  9. Percentage of Participants Initiating Insulin Glargine During Weeks 20-54

    Percentage of participants who initiated insulin glargine therapy from Weeks 20 through 54 was reported.

    Time frame: Week 20 up to Week 54

Other outcomes

  1. Baseline A1C

    Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.

    Time frame: Baseline

07

Results

Posted Oct 5, 2020

Participant flow

The study recruited participants in clinics/clinical offices in 28 countries. One participant who was randomized to the arm "Sitagliptin/Metformin" withdrew prior to treatment, then was re-randomized into the study. Only the second randomization is counted for Participant Flow and All-Cause Mortality, so this participant is not counted twice.

Weeks 0-20
Participant flow — Weeks 0-20
MilestoneSitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XR
Started62624751
Treated62624551
Completed59624247
Not completed3054
Withdrew: Consent withdrawn by parent/guardian0013
Withdrew: Withdrawal by subject2010
Withdrew: Lost to follow-up1011
Withdrew: Randomized but not treated0020
Weeks 20-54
Participant flow — Weeks 20-54
MilestoneSitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XR
Started28304247
Completed25283943
Not completed3234
Withdrew: Consent withdrawn by parent/guardian1110
Withdrew: Withdrawal by subject2112
Withdrew: Lost to follow-up0012

Outcome measures

PrimaryChange From Baseline in A1C at Week 20

Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline at Week 20 was estimated from a longitudinal data analysis model.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · Percentage of glycated hemoglobin
Change From Baseline in A1C at Week 20
Percentage of glycated hemoglobinSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Change From Baseline in A1C at Week 20-0.58 (-0.94 to -0.22)-0.09 (-0.43 to 0.26)
Statistical analysis
  • Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled vs Metformin and Metformin XR Pooled · Mixed Models Analysis · p = = 0.018 · Least squares mean difference: -0.49 · 95% CI -0.90 to -0.09
PrimaryNumber of Participants Who Experienced ≥1 Adverse Event During Weeks 0-20

The number of participants experiencing ≥1 adverse event during Weeks 0-20 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-20
ParticipantsSitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-20424629307176
Statistical analysis
  • Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled vs Metformin and Metformin XR Pooled · Difference in percentage: -1.3 · 95% CI -13.9 to 11.3The Miettinen and Nurminen methodology was used to calculate the difference and 95% confidence interval.
PrimaryNumber of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-20

The number of participants who discontinued from study drug due to an adverse event during Weeks 0-20 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-20
ParticipantsSitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-20122234
Statistical analysis
  • Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled vs Metformin and Metformin XR Pooled · Difference in percentage: -0.5 · 95% CI -6.2 to 5.0The Miettinen and Nurminen methodology was used to calculate the difference and 95% confidence interval.
PrimaryNumber of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56

The number of participants experiencing ≥1 adverse event during Weeks 0-56 were reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to approximately Week 56
Reported as:
Count of participants · Participants
Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56
ParticipantsSitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Number of Participants Who Experienced ≥1 Adverse Event During Weeks 0-56262736396266
Statistical analysis
  • Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled vs Metformin and Metformin XR Pooled · Difference in percentage: 2.9 · 95% CI -8.9 to 14.4The Miettinen and Nurminen methodology was used to calculate the difference and 95% confidence interval.
PrimaryNumber of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54

The number of participants who discontinued from study drug due to an adverse event during Weeks 0-54 was reported. An adverse event is defined as any untoward medical occurrence in a person administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to Week 54
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54
ParticipantsSitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event During Weeks 0-54111324
Statistical analysis
  • Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled vs Metformin and Metformin XR Pooled · Difference in percentage: -2.1 · 95% CI -10.1 to 5.8The Miettinen and Nurminen methodology was used to calculate the difference and 95% confidence interval.
SecondaryChange From Baseline in A1C at Week 54

A1C is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Mean change from baseline at Week 54 was estimated from a longitudinal data analysis model.

Time frame:
Baseline and Week 54
Reported as:
Least squares mean · Percentage of glycated hemoglobin
Change From Baseline in A1C at Week 54
Percentage of glycated hemoglobinSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Change From Baseline in A1C at Week 540.35 (-0.48 to 1.19)0.73 (-0.08 to 1.54)
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 20

Blood glucose was measured on a fasting basis. Mean change from baseline at Week 20 was estimated from a longitudinal data analysis model.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20
mg/dLSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 20-2.5 (-16.7 to 11.7)8.3 (-5.0 to 21.6)
Statistical analysis
  • Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled vs Metformin and Metformin XR Pooled · Mixed Models Analysis · p = = 0.159 · Least squares mean difference: -10.8 · 95% CI -25.9 to 4.3
SecondaryChange From Baseline in FPG at Week 54

Blood glucose was measured on a fasting basis. Mean change from baseline at Week 54 was estimated from a longitudinal data analysis model.

Time frame:
Baseline and Week 54
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG at Week 54
mg/dLSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Change From Baseline in FPG at Week 5416.8 (-8.4 to 42.0)16.9 (-7.0 to 40.8)
SecondaryPercentage of Participants With A1C at Goal (<7.0%) at Week 20

Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<7.0%) at Week 20 was presented.

Time frame:
Week 20
Reported as:
Number · Percentage of participants
Percentage of Participants With A1C at Goal (<7.0%) at Week 20
Percentage of participantsSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Percentage of Participants With A1C at Goal (<7.0%) at Week 2043.031.0
Statistical analysis
  • Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled vs Metformin and Metformin XR Pooled · Miettinen and Nurminen · p = 0.017 · Difference in percentage: 16.0 · 95% CI 2.9 to 28.9
SecondaryPercentage of Participants With A1C at Goal (<6.5%) at Week 20

Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<6.5%) at Week 20 was presented.

Time frame:
Week 20
Reported as:
Number · Percentage of participants
Percentage of Participants With A1C at Goal (<6.5%) at Week 20
Percentage of participantsSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Percentage of Participants With A1C at Goal (<6.5%) at Week 2029.020.4
Statistical analysis
  • Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled vs Metformin and Metformin XR Pooled · Miettinen and Nurminen · p = 0.049 · Difference in percentage: 12.2 · 95% CI 0.0 to 24.8
SecondaryPercentage of Participants With A1C at Goal (<7.0%) at Week 54

Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<7.0%) at Week 54 was presented.

Time frame:
Week 54
Reported as:
Number · Percentage of participants
Percentage of Participants With A1C at Goal (<7.0%) at Week 54
Percentage of participantsSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Percentage of Participants With A1C at Goal (<7.0%) at Week 5431.427.3
SecondaryPercentage of Participants With A1C at Goal (<6.5%) at Week 54

Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Percentage of participants with A1C at goal (\<6.5%) at Week 54 was presented.

Time frame:
Week 54
Reported as:
Number · Percentage of participants
Percentage of Participants With A1C at Goal (<6.5%) at Week 54
Percentage of participantsSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Percentage of Participants With A1C at Goal (<6.5%) at Week 5418.619.5
SecondaryPercentage of Participants Initiating Glycemic Rescue Therapy by Week 20

Percentage of participants who initiated glycemic rescue therapy prior to Week 20 was reported.

Time frame:
Up to Week 20
Reported as:
Number · Percentage of participants
Percentage of Participants Initiating Glycemic Rescue Therapy by Week 20
Percentage of participantsSitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Percentage of Participants Initiating Glycemic Rescue Therapy by Week 203.219.44.413.73.716.8
Statistical analysis
  • Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled vs Metformin and Metformin XR Pooled · Log-Rank Test · p = 0.002 · Kaplan-meier difference in percentage: -13.2 · 95% CI -21.1 to -5.3
SecondaryPercentage of Participants Initiating Insulin Glargine During Weeks 20-54

Percentage of participants who initiated insulin glargine therapy from Weeks 20 through 54 was reported.

Time frame:
Week 20 up to Week 54
Reported as:
Number · Percentage of participants
Percentage of Participants Initiating Insulin Glargine During Weeks 20-54
Percentage of participantsSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Percentage of Participants Initiating Insulin Glargine During Weeks 20-5422.726.6
Other pre-specifiedBaseline A1C

Glycated hemoglobin (A1C) is a blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.

Time frame:
Baseline
Reported as:
Mean · Percentage of glycated hemoglobin
Baseline A1C
Percentage of glycated hemoglobinSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
Baseline A1C7.96 ± 1.118.06 ± 1.07

Adverse events

Collected over Up to 56 weeks for non-serious adverse events. Up to approximately 76 weeks for serious adverse events. Up to approximately 78 weeks for all-cause mortality.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin/Metformin1/62 (1.6%)4/62 (6.5%)34/62 (54.8%)
Metformin0/62 (0%)3/62 (4.8%)40/62 (64.5%)
Sitagliptin/Metformin XR0/47 (0%)3/45 (6.7%)30/45 (66.7%)
Metformin XR0/51 (0%)3/51 (5.9%)36/51 (70.6%)
Sitagliptin/Metformin and Sitagliptin/Metformin XR Pooled1/109 (0.9%)7/107 (6.5%)64/107 (59.8%)
Metformin and Metformin XR Pooled0/113 (0%)6/113 (5.3%)76/113 (67.3%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventSitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
DiarrhoeaGastrointestinal disorders0/620/621/450/511/1070/113
GastroenteritisInfections and infestations0/620/621/450/511/1070/113
Upper respiratory tract infectionInfections and infestations0/620/621/450/511/1070/113
Abdominal pain upperGastrointestinal disorders0/620/620/451/510/1071/113
VomitingGastrointestinal disorders0/620/620/451/510/1071/113
H1N1 influenzaInfections and infestations0/620/620/451/510/1071/113
HyperglycaemiaMetabolism and nutrition disorders0/621/620/451/510/1072/113
Suicide attemptPsychiatric disorders0/620/620/451/510/1071/113
Type I hypersensitivityImmune system disorders1/620/620/450/511/1070/113
PyelonephritisInfections and infestations1/620/620/450/511/1070/113
Most frequent other events
Showing 10 of 20
Most frequent other events
EventSitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRSitagliptin/Metformin and Sitagliptin/Metformin XR PooledMetformin and Metformin XR Pooled
HypoglycaemiaMetabolism and nutrition disorders10/626/629/4510/5119/10716/113
HeadacheNervous system disorders3/628/622/4510/515/10718/113
Upper respiratory tract infectionInfections and infestations9/626/625/453/5114/1079/113
DiarrhoeaGastrointestinal disorders7/624/621/453/518/1077/113
NasopharyngitisInfections and infestations7/627/621/452/518/1079/113
PharyngitisInfections and infestations1/623/621/455/512/1078/113
Abdominal painGastrointestinal disorders2/624/624/454/516/1078/113
NauseaGastrointestinal disorders2/625/624/452/516/1077/113
GastroenteritisInfections and infestations5/623/623/452/518/1075/113
Urinary tract infectionInfections and infestations0/625/623/451/513/1076/113

Baseline characteristics

The baseline characteristics data are presented for all treated participants.

Age, Continuous
Age, Continuous(years)Sitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRTotal
Mean14.4 ± 2.213.9 ± 1.814.8 ± 1.914.9 ± 1.614.4 ± 1.9
Age, Customized
Age, Customized(Participants)Sitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRTotal
In utero00000
Preterm newborn infants (gestational age < 37 wks)00000
Newborns (0-27 days)00000
Infants and toddlers (28 days-23 months)00000
Children (2-11 years)1073121
Adolescents (12-17 years)52554250199
Adults (18-64 years)00000
From 65-84 years00000
85 years and over00000
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRTotal
Female41403232145
Male2122131975
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRTotal
Hispanic or Latino2323112077
Not Hispanic or Latino35362928128
Unknown or Not Reported435315
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRTotal
American Indian or Alaska Native013913
Asian212215664
Native Hawaiian or Other Pacific Islander11002
Black or African American222410
White2423222796
More than one race14133535
Unknown or Not Reported00000
Glycated Hemoglobin (A1C)
Glycated Hemoglobin (A1C)(Percentage)Sitagliptin/MetforminMetforminSitagliptin/Metformin XRMetformin XRTotal
Mean8.02 ± 1.228.13 ± 1.087.87 ± 0.947.97 ± 1.058.0 ± 1.1
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Jalaludin MY, Deeb A, Zeitler P, Garcia R, Newfield RS, Samoilova Y, Rosario CA, Shehadeh N, Saha CK, Zhang Y, Zilli M, Scherer LW, Lam RLH, Golm GT, Engel SS, Kaufman KD, Shankar RR. Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. Pediatr Diabetes. 2022 Mar;23(2):183-193. doi: 10.1111/pedi.13282. Epub 2021 Dec 20. PubMed 34779103 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2011 to primary completion in Sep 2019, 93 months.

Results were first posted in Oct 2020, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 93 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2013
First posted
Jan 4, 2013
StartActual
Dec 7, 2011
Primary completionActual
Sep 17, 2019
CompletionActual
Sep 17, 2019
Results first posted
Oct 5, 2020
Last update
Sep 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01760447
Responsible party
Sponsor
First posted
Jan 4, 2013
Start date
Dec 7, 2011
Primary completion
Sep 17, 2019
Completion
Sep 17, 2019
Results posted
Oct 5, 2020
Last update
Sep 23, 2022

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Metformin

Start the discussion